MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.011
+0.051
+5.31%
Opening 09:50 11/29 EST
OPEN
1.000
PREV CLOSE
0.9600
HIGH
1.030
LOW
0.9700
VOLUME
194.29K
TURNOVER
0
52 WEEK HIGH
1.840
52 WEEK LOW
0.2426
MARKET CAP
190.46M
P/E (TTM)
-3.0535
1D
5D
1M
3M
1Y
5Y
BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4
Benzinga · 3h ago
Weekly Report: what happened at AKBA last week (1120-1124)?
Weekly Report · 2d ago
Akebia Therapeut: Current report
Press release · 11/21 23:02
Weekly Report: what happened at AKBA last week (1113-1117)?
Weekly Report · 11/20 10:42
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $5
Benzinga · 11/17 12:10
Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Akebia Therapeutics (AKBA)
TipRanks · 11/17 11:31
Weekly Report: what happened at AKBA last week (1106-1110)?
Weekly Report · 11/13 10:36
Akebia Therapeut: Current report
Press release · 11/08 13:04
More
About AKBA
Akebia Therapeutics, Inc. is an integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The Company's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The Company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.